T1	Participants 524 696	patients with chronic hepatitis C were treated with IFN-alpha plus ribavirin [17] and randomized for treatment with amantadine (200 mg/day, orally, n=136) or placebo (n=131
T2	Participants 300 408	patients with chronic hepatitis C during and after treatment with interferon-alpha (IFN-alpha) and ribavirin
